📅 PUBMED DAILY TRIAGE — 2026-05-06

Window: 2026-05-05T09:00:00Z → 2026-05-06T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~100 candidates | Kept for output: 20 High priority (8+): 2 | Standard (5–7): 18 | Low/archive: discarded | Unsolicited finds: 1 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Hematologic Malignancies (AML, MDS, CLL, MPN, lymphoma)

TR-2026-05-06-001 / PMID 42085510 · Clinical implications of variant allele frequencies of genes in patients with acute myeloid leukemia · 8/10 · 🟢 NEAR_TERM_IMPLEMENTABLE

Zhao L et al. — The Oncologist (2026 May 5) · Retrospective cohort N=254 + external validation · VAF cutoffs for 7 AML mutations (DNMT3A, FLT3-ITD, NPM1, SF3B1, TP53, ASXL1, CEBPA) combined with cytogenetics stratify non-transplant AML patients into distinct low/intermediate/high-risk groups (all P<0.05), outperforming binary mutation status — a near-implementable refinement to ELN 2022 risk classification. DOI: 10.1093/oncolo/oyag099

Early Cancer Detection (liquid biopsy, ctDNA, cfDNA)

TR-2026-05-06-002 / PMID 42086163 · Postoperative MRD status Refines Recurrence Risk Stratification Beyond Pathologic Response After Neoadjuvant Chemoradiotherapy for ESCC · 8/10 · 🔴 EARLY_CANCER_DETECTION

Liu Z et al. — J Thorac Cardiovasc Surg (2026 May 3) · Post-hoc of prospective preSINO trial, N=93 · Postoperative ctDNA MRD (HR=13.62) completely supersedes pathologic complete response for ESCC recurrence prediction; 1-year recurrence rates: 3.7% (pCR+MRD-neg) vs 82.4% (non-pCR+MRD-pos) — directly actionable for adjuvant therapy decisions. DOI: 10.1016/j.jtcvs.2026.04.014

🟢⚪ STANDARD (5–7) — Top by Topic

Hematologic Malignancies

• PMID 42086932 · MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in MPN · 7/10 · Treatment Innovation | Al-Ali HK et al. — Leukemia (Nature group). Comprehensive review: AML Phase III was negative; myelofibrosis shows meaningful spleen/symptom/molecular responses; MDM2 degraders + JAK/BCL-2 combinations emerging. DOI: 10.1038/s41375-026-02975-6
• PMID 42086343 · CCR7/H3K9me3 co-expression identifies aggressive B-cell lymphoma with bone marrow infiltration · 6/10 · Diagnostics | Chen J et al. — Eur Cytokine Netw. Dual IHC biomarker defines worst-prognosis B-cell lymphoma subgroup; mechanistic CCR7→H3K9me3 link confirmed. DOI: 10.32604/ecn.2026.077875
• PMID 42086953 · Checkpoint inhibitor hematologic irAEs and disease recurrence in hematolymphoid malignancies · 5/10 · Treatment Innovation | Ben Lamine C et al. — Blood Res. Emerging evidence hem-irAEs may predict treatment response; hypothesis-generating review. DOI: 10.1007/s44313-026-00135-4

Early Cancer Detection / Liquid Biopsy

• PMID 42086706 · Predicting immunotherapy benefit in leiomyosarcoma through cfDNA active chromatin profiling · 7/10 · Early Detection | Lopes CDH et al. — npj Precis Oncol. Novel cfDNAac epigenomic liquid biopsy predicts CBR and PFS in 30 LMS patients; B/T-cell activation signatures = responders. DOI: 10.1038/s41698-026-01451-9
• PMID 42086381 · How DNA methylation predicts response to cancer therapies · 6/10 · Genomics/Precision Medicine | Davalos V, Ferrer G, Esteller M — Trends Cancer. Synthesis of methylation-therapy response evidence + liquid biopsy validation roadmap (Esteller group). DOI: 10.1016/j.trecan.2026.04.002

Precision Oncology & Genomic Medicine

• PMID 42085620 · Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies · 7/10 · Genomics/Precision Medicine | Willmann J, Dee EC et al. — JCO (MSK-led). Proposes lesion-level spatiotemporal "metastatic trajectory" framework to guide adaptive local/systemic therapy; ctDNA + radiomics identified as tracking tools. DOI: 10.1200/JCO-25-01958
• PMID 42083301 · 4-Gene NGS Panel for Predicting Papillary Thyroid Carcinoma in Indeterminate Cytology: Multicenter Study in China · 6/10 · Diagnostics | Jiao Q et al. — Cancer Med. Cost-effective, multicenter validated NGS panel addresses the clinical problem of unnecessary thyroid surgeries for indeterminate cytology. DOI: 10.1002/cam4.71924

AI/ML in Clinical Diagnostics

• PMID 42086912 · Multi-scale data improves ML model for long COVID identification (NIH All of Us, N>17,200) · 6/10 · Diagnostics | Guardo C et al. — Commun Med. Multi-scale EHR+survey+genomic approach achieves AUC 0.748 vs EHR-only 0.736; active-duty service and fatigue top predictors. DOI: 10.1038/s43856-026-01621-7
• PMID 42086622 · Topology-preserving DL for conjunctival vessel segmentation and tortuosity in diabetes · 6/10 · Diagnostics | Mohamed Naim A et al. — Sci Rep. Novel non-invasive microvascular phenotyping from external eye imaging; tortuosity elevated in diabetes, consistent with retinal findings. DOI: 10.1038/s41598-026-48680-3
• PMID 42083734 · Spatial and volumetric characteristics of glioblastoma: associations with clinical presentation and survival · 5/10 · Diagnostics | Zhou DJ et al. — Ann Clin Transl Neurol (Penn Medicine, Davatzikos lab). DOI: 10.1002/acn3.70420

Novel Therapeutics (Immunotherapy / CAR-T / Targeted)

• PMID 42086291 · TACE-based combination therapy as potential new standard for intermediate-stage HCC (EMERALD-1, LEAP-012) · 6/10 · Treatment Innovation | Chen S et al. — BMJ Open Gastroenterol. Landmark trial synthesis; PFS benefit confirmed, OS inconsistent; precision stratification using tumor burden + ctDNA is the next step. DOI: 10.1136/bmjgast-2025-002154
• PMID 42085851 · Chemokine-directed strategies to improve CAR-T infiltration into solid tumors · 5/10 · Treatment Innovation | Hu J — Int Immunopharmacol. Structured review of CXCR3/CCR2/CCR7 axes for CAR-T engineering; key barrier to solid tumor CAR-T efficacy. DOI: 10.1016/j.intimp.2026.116783

Cardiovascular-Metabolic

• PMID 42083504 · Gut microbiota and immunometabolism in obesity · 6/10 · Drug Development | Torres-Mayo A et al. — Gut Microbes. Comprehensive framework linking SCFA/bile acid/amino acid metabolites to mTOR/AMPK immune reprogramming in obesity; modulation strategy outlined. DOI: 10.1080/19490976.2026.2667610
• PMID 42086622 (also AI/ML, see above)

Aging, Longevity & Population Health

• PMID 42087064 · Healthy Eating Index, Epigenetic Age Acceleration and Mortality Risk in US Adults (NHANES + HRS, N=3,910) · 7/10 · Prevention | Beydoun MA et al. — Aging Cell (NIA/NIH). GrimAgeEAA HR=1.61–1.76/SD; ~44% of diet–mortality benefit mediated by epigenetic aging (HRS); physical activity key confounder. DOI: 10.1111/acel.70504
• PMID 42083402 · Australian Consensus Statement on Frailty Prevention and Management in Community-Dwelling Older Adults (Modified Delphi) · 7/10 · Prevention | Chopra S et al. — Med J Aust. National clinical guideline: screening, physical activity, nutrition, polypharmacy, multidisciplinary care for frailty. DOI: 10.5694/mja2.e70182
• PMID 42083130 · Melatonin reshapes LOH treatment by targeting Leydig cell senescence · 5/10 · Drug Development | Wu H et al. — Aging Cell. Mechanistic review proposing melatonin for active cellular repair vs passive testosterone supplementation in LOH. DOI: 10.1111/acel.70492

Rare Diseases

• PMID 42083118 · Optimizing Oligonucleotide Therapeutics: A Model-Informed Drug Development Perspective · 5/10 · Drug Development | Yuan Y et al. (FDA) — Clin Transl Sci. MIDD frameworks for ASO/siRNA/aptamer development; critical for rare disease trial efficiency. DOI: 10.1111/cts.70570

💡 UNSOLICITED FINDS

PMID 42083273 · Cervical Cancer Screening Utilization Among Female Health Workers in Ethiopia: Systematic Review and Meta-Analysis · 6/10 · 🟡 UNDERSERVED_POPULATION

Usso AA et al. — J Obstet Gynaecol Res (2026 May). Quantifies cervical cancer screening utilization in Ethiopian female HCWs — a doubly strategic population (personal risk + multiplier for broader programs) in a region with disproportionately high cervical cancer mortality. DOI: 10.1111/jog.70313

📊 TODAY'S BREAKDOWN

By research category:

• Diagnostics: 6
• Treatment Innovation: 5
• Prevention: 3
• Genomics/Precision Medicine: 3
• Drug Development: 3
• Early Detection: 2 (standalone)
• Public Health: 1
• Other: 0

By evidence maturity:

• Exploratory: 14
• Validated: 5
• Potentially Practice-Changing: 1

By watchlist topic (reviewed / kept / highest score):

By source type: peer_reviewed: 20 | preprint: 0

Topics with zero 8+ articles this run: CBC/ML hematology, AI/ML diagnostics, Precision oncology, Novel therapeutics, Cardiovascular-metabolic, Aging/longevity, Rare diseases

🔧 RUN NOTES

• Window expansion: NOT triggered (20 relevant records found, exceeds 5-article threshold)
• Truncation: esummary responses truncated at 20K chars; resolved by targeted efetch for high-interest PMIDs. No records silently dropped — all candidates reviewed via abstract before classification.
• CBC/ML hematology: 14th consecutive empty high-priority window. Best candidate this run (PMID 42086912, Long COVID ML) is AI/EHR-driven, not strictly CBC-based. Watchlist query is functioning; topic appears to be in a low-signal period.
• Aging/longevity: humans[MeSH] filter applied (per 2026-05-04 fix). Zero non-human noise — filter continues to be effective.
• Cardiovascular-metabolic: 252 raw hits but very high noise. GLP-1/SGLT2-specific clinical trials not in today's CRDT window; topic dominated by observational diabetes/obesity studies.
• PMID 42086706 (cfDNAac, Aqtual platform): Commercial conflict declared. Phase 2 pipeline should weight accordingly.
• Rolling 7-day view (topics consistently zero 8+): CBC/ML hematology = 14 consecutive days; Rare diseases = 5 of last 7 days; Cardiovascular-metabolic GLP-1/SGLT2 = 4 of last 7 days. Monitor for search query drift or indexing gaps.